Immunotherapy is becoming an integral player in cancer treatment, and with so many products in clinical trials, that role will only expand. These advances, exciting as they are, also introduce a new era of toxicity management to oncology—an era that experts say can be unpredictable and challenging.
“These agents can yield remarkable results,” said Patrick Medina, PharmD, a professor in the Department of Medicine at Stephenson Cancer Center at the University of Oklahoma, in